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In 2009, Lombardi et al. reported their startling ﬁnding that the gammaretrovirus xenotropic murine leukemia virus-related
retrovirus (XMRV) is present in 67% of blood samples of patients suﬀering from chronic fatigue syndrome (CFS), as opposed
to only 3.7% of samples from healthy individuals. However, we and others could not conﬁrm these results, using a nested PCR
assay. An alternative to this highly sensitive, but contamination-prone, technique is to measure the serological response to XMRV.
Thus, we tested the plasma samples from our cohorts of CFS patients and healthy controls for the presence of XMRV-speciﬁc
antibodies. Using two novel chemiluminescence immunoassays (CMIAs), we show that none of our samples have any XMRV-
reactive antibodies. Taken together with our previous ﬁndings, we conclude that XMRV is not present in any human individual
tested by us, regardless of CFS or healthy control.
1.Introduction
In 2006, Urisman et al. identiﬁed a new gammaretrovirus
in prostate cancer samples harboring a mutation in a viral
defense gene known as RNASEL [1]. This new virus, xeno-
tropic murine leukemia virus-related retrovirus (XMRV),
was found to be a close relative to known murine leukemia
viruses (MLVs) and was the ﬁrst documented case of human
infection with a xenotropic retrovirus. Although XMRV was
originally associated with the mutant variant of the RNASEL
gene, further research could not conﬁrm this association but
did ﬁnd it in about 10% of prostate cancers [2].
The discovery of a new virus that could infect humans
lead Lombardi et al. [3]t ot e s tf o rt h ev i r u si np a t i e n t s
suﬀering from chronic fatigue syndrome (CFS). CFS is a dis-
ease of unknown etiology that manifests as neurological,
immunological, and endocrinological dysfunctions. A wide
range of viruses have been investigated in the past as caus-
ative agents of CFS; however, ﬁndings were mixed, and no
conclusive evidence of one virus causing CFS has been im-
plicated [4]. Using a nested polymerase chain reaction
(PCR), Lombardi et al. found that blood samples of 68 out of
101 (67%) CFS patients contained the XMRV gag sequence,
as opposed to only 8 out of 212 (3.7%) samples from healthy
individuals [3].Theﬁnding ofaviruslinked toCFSreignited
excitement in the ﬁeld, leading many laboratories around
the world to test for this new virus, but the excitement has
been short lived. Although some support linking XMRV or
MLVs and CFS has been published [3, 5, 6], it has been
overshadowed by reports failing to detect the virus in CFS
patients [7–20], including a study done by us.
Inouroriginalpaper[17],wefailedtoﬁndanassociation
between CFS patients and XMRV, using PCR technology.
However, we did detect some XMRV sequences as well as
other MLV sequences in some of our samples. Due to the
close relationship between XMRV and MLVs, which are2 Advances in Virology
present throughout the mouse genome, we tested all of our
samples for mouse DNA using a TaqMan qPCR assay for
murinemitochondrialcytochromeoxidase,cox2[14],aswell
as a single PCR assay for the highly abundant intracisternal
A-type particle (IAP) long terminal repeat sequence, devel-
oped by our group [17]. We found that every sample that
contained an XMRV or MLV sequence was also positive for
mouse DNA contamination. Although we did not claim that
our ﬁndings provided a full explanation of the origin of
XMRV, we put forward a cautionary tale about the risks of
mouse DNA contamination in various common laboratory
reagents.
One of the criticisms of our study [17] was that we only
used PCR technology to test for the presence of XMRV, while
the original paper also included serological analyses [3]. Spe-
c i ﬁ c a l l y ,s o m eg r o u p sh a v ed e v e l o p e dn o v e ls e r o l o g i c a lt e s t s
utilizing western blots and ELISAs in the search for anti-
XMRV antibodies, because the presence of antibodies could
not be due to mouse DNA contamination [3, 8, 13, 14, 20,
21].Recently,twoprototypedirectformatchemiluminescent
immunoassays (CMIAs) were developed to detect XMRV-
speciﬁc antibodies [22]. Both CMIAs utilize a direct assay
format in which recombinant p15E or gp70 protein serves
as both capture and detection antigens. The assays demon-
strated excellent sensitivity, detecting early seroconversion
bleeds in XMRV-infected rhesus macaques [22]. Moreover,
these assays were also shown to detect speciﬁc antibodies to
MLVs [22]. In this study, we use these two sensitive CMIAs
to screen plasma samples from our blinded cohorts for the
presence of XMRV-speciﬁc antibodies. No samples from our
cohort of over 100 CFS patients were positive in either of
these assays, while two samples from the healthy control
cohort tested positive in one of the CMIA assays; however,
reactivity of these same samples was not conﬁrmed by west-
ern blot. Thus, these highly sensitive serological studies have
conﬁrmedourpriorconclusionthatthepositiveXMRVPCR
results were a result of mouse DNA contamination, since no
antibodies against XMRV were present.
2.MaterialsandMethods
2.1. Sample Collection. All samples were collected according
to the institutional guidelines of Tufts University, after re-
ceiving informed consent. The 36 healthy individuals (15
females and 21 males) were recruited on a voluntary basis
by the Huber laboratory and were between 18 and 65 years
of age. The 112 CFS patients (90 females, 20 males, and 3
unknown), recruited by Dr. Susan Levine, were between 18
and 65 years of age and resided in the Northeastern United
States. All patients were diagnosed for CFS according to the
CDC criteria, and the majority was completely disabled. The
cohortcomprisedacombinationofthosewithanabruptand
others with a gradual onset of symptoms.
2.2. Preparation of Human Blood and Plasma Samples. Ap-
proximately 30mL of blood were drawn into three hepar-
inizedtubes(BectonDickinson)andshippedovernight(CFS
patients) or processed immediately (healthy controls). The
blood collection tubes from each individual were consoli-
dated into one 50mL tube and diluted with PBS, containing
CaCl2 and MgCl2 (sigma) at a 1:1 ratio. 15mL of Ficoll (GE
Healthcare) was added to two new 50mL tubes, and 25mL
of the diluted blood was gently layered on top of the Ficoll,
followed by a 30min centrifugation in a Sorvall RT7 plus
rotor at 2000rpm at room temperature. The PBMCs were
collected from the interface following the spin and were used
forDNAisolation.TenmLofplasmawerealsocollectedfrom
each sample and stored at −80◦C. One ml of plasma was sent
to Abbott Labs on dry ice overnight for further testing.
2.3. XMRV Chemiluminescent Immunoassays (CMIAs). A
detailed procedure can be seen here [22]. Brieﬂy, 100µLo f
neat plasma were screened for antibodies to XMRV gp70 and
p15EproteinsusingtwoprototypeARCHITECTchemilumi-
nescent immunoassays (CMIAs; Abbott Diagnostics, Abbott
Park,Ill).TheCMIAsutilizeadirectassayformatinwhichE.
coli-expressed XMRV p15E or mammalian-expressed XMRV
gp70 were used as both capture and detection antigens.
Assay positive controls were derived from XMRV-infected
macaque plasmas at 1:1000 (PC1) or 1:4000 (PC2). A
pool of normal human plasma was used as negative control
(NC) and as sample diluents. Cutoﬀ (CO) values of the
ARCHITECT CMIAs were calculated based on the following
formulas: CO = 0.45 × (Calibrator 1 Mean Relative Light
Units (RLU)) for p15E CMIA and CO = 0.078 × (Calibrator
2 Mean RLU) for gp70 CMIA. Assay results were reported
as the ratio of the sample RLU to the cutoﬀ RLU (S/CO)
for each specimen. Specimens with S/CO values <1.00 were
considered nonreactive; specimens with S/CO values ≥1.00
were considered initially reactive. The S/CO values of the
NC, PC1, and PC2 were 0.16, 12.8, and 3.5 for the gp70
CMIA and 0.13, 7.4, and 2.2 for the p15E CMIA. Initially
reactive specimens were retested in duplicate by either
ARCHITECT p15E or gp70 CMIAs. Repeatedly reactive
specimens were analyzed at 1:100 dilution by investigational
western blot assays using puriﬁed XMRV viral lysate as well
as recombinant gp70 protein.
2.4. Western Blot Analysis. Western blot (WB) analysis using
puriﬁed XMRV viral lysate as well as recombinant gp70
protein was performed as described [22]. Brieﬂy, viral lysate
(80µg/gel) or recombinant gp70 protein (20µg/gel) were
separated by electrophoresis on a 4–12% NuPAGE Bis-Tris
2-dimension gel (Invitrogen, Carlsbad, Calif) in the presence
of sodium dodecyl sulfate (SDS). The protein bands on the
gel were electrophoretically transferred to a polyvinylidene
diﬂuoride (PVDF) membrane (invitrogen). After blocking,
the PVDF membrane was cut into 2mm strips. Strips were
incubated with human samples diluted 1:100 or XMRV-
infected macaque plasma diluted 1:200 overnight at 2–8◦C.
After removal of unbound antibodies, strips were incubated
with alkaline phosphatase conjugated goat antihuman IgG
(Southern Biotech, Birmingham, Ala) for 30 minutes at
room temperature. The strips were washed, and chromoge-
nic substrate solution was added.Advances in Virology 3
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Figure 1: Distribution of p15E CMIA (a) and gp70 CMIA (b) log
N of S/CO on 148 samples collected from 112 CFS patients and 36
healthy controls. Numbers of specimens within each log N of S/CO
value are shown above the solid bars. Assay cutoﬀsw e r ee q u i v a l e n t
to mean 16 SD and 12 SD for p15E and gp70 CMIAs, respectively,
based on blood donor populations [22]. Log N of S/CO, natural log
transformation of S/CO.
3. Results
148 blinded plasma samples from our original CFS and
healthy control cohorts were analyzed for the presence of
XMRV-speciﬁc antibodies, using the direct format ARCHI-
TECT p15E and gp70 CMIAs. None of the 148 plasma sam-
ples were reactive in the p15E CMIA (Figure 1(a)). Two of
the 148 samples (ID = 137, 138) were positive in the gp70
CMIA (Figure 1( b ) ) .B o t hs p e c i m e n sw e r ew e a k l yr e a c t i v ei n
the gp70 CMIA with sample/cut-oﬀ (S/CO) values of 7.77
(log N of S/CO = 2.05) and 9.02 (log N of S/CO = 2.20),
respectively. Although the samples were repeat reactive in
the gp70 CMIA, they were not reactive by WB. As shown
in Figure 2, both samples showed no visible WB bands
using either XMRV viral lysate proteins (Figure 2(a))o r
recombinant gp70 protein (Figure 2(b)). Unblinding of the
samplesrevealedthatthetwogp70reactivesamplesstemmed
from two sequential blood collections of a single healthy
control (Table 1).
4. Discussion
In our original study, we found no speciﬁc relationship
between the presence of XMRV and CFS [17]. However,
screening the genomic DNA from peripheral blood lympho-
cytes of both healthy control and CFS cohorts, we did detect
PCR products that were identical to XMRV gag sequences, as
well as other MLV gag sequences. Due to the high number
of MLV sequences in the mouse genomic DNA, we found
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Figure 2: WB analysis of gp70 CMIA reactive samples with (a)
native XMRV viral proteins and (b) recombinant gp70. WB strip
key: 1 & 2: gp70 reactive samples 137 and 138; 3: normal blood
donor plasma as negative control; 4: XMRV-infected macaque
plasma as positive control. The faint white band in the 65–70kd
region in (B, strips no. 1–3) indicates a lack of speciﬁc anti-gp70
antibody.
it prudent to test for mouse DNA contamination in our
samples. Using both a test developed by the Switzer lab at
CDC for mouse mitochondrial DNA [14], as well as a test
developed by the Coﬃn lab for the IAP [17], we found that
every sample that was positive for XMRV or other MLVs
PCR products was also positive for mouse DNA. Although
these data provide an explanation for the detection of MLV
sequences in our samples, they do not rule out the possibility
thatXMRVandmouseDNAcontaminationcouldbepresent
inthesamesample.Toclarifythisissue,wetestedourplasma
samples for the presence of XMRV-speciﬁc antibodies.
Recent animal studies showed that XMRV infection elic-
ited a potent humoral immune response in rhesus macaques
[22]. The infected macaques developed XMRV-speciﬁc anti-
bodies within two weeks of infection and persisted more
than 158 days. The predominant responses were to all three
structural proteins of XMRV: the envelope protein gp70,
the transmembrane protein p15E, and the capsid protein
p30 [22]. Sensitivity of both p15E and gp70 CMIAs was
validated by the animal model; both CMIAs were able to
detect p15E or gp70 speciﬁc antibodies as early as day 9 after
infection [22]. In contrast, we were unable to detect XMRV
p15E or gp70 speciﬁc antibodies in the 112 CFS patients
and the 36 healthy controls. Although 2 samples from the
same healthy control had weak reactivity in gp70 CMIA,
the reactivity was not conﬁrmed by recombinant gp70 WB.
Furthermore, both samples were nonreactive in p15E CMIA
and had no detectable p15E and p30 antibodies by viral
lysate WB. Considered in combination with the negative
PCR data, the observed isolated and weak gp70 reactivity4 Advances in Virology
Table 1: Results summary for XMRV positive PCR samples. All samples that tested positive for XMRV gag sequence in original study [17],
as well as the two samples that reacted with the gp70 CMIA, are displayed. Bolded samples showed the VP42 gag sequence but did not react
with the CMIAs. The italic data shows the two samples that were reactive in the gp70 CMIA. CMIA values less than one are considered
nonreactive. XMRV GAG: Nested gag PCR. Mcox: murine mitochondrial cytochrome oxidase qPCR. IAP: Intracisternal A-type particle
PCR.
Initial Initial Repeat
PCR results test test test
XMRV p15E gp70 gp70
ID Unblinded ID GAG Mcox IAP S/CO S/CO S/CO
72 TH72.1 + + + 0.38 0.06
128 TH04.1 + + + 0.16 0.07
129 TH01.7 + + + 0.15 0.06
131 TH01.8 + − + 0.12 0.06
132 TH01.3 + + + 0.15 0.06
134 TH06.1 + + + 0.15 0.07
135 TH01.1 + + + 0.14 0.09
136 TH05.1 + + + 0.16 0.06
137 TH07.1 + + + 0.16 7.77 7.17, 7.21
138 TH07.2 −− − 0.14 9.02 8.65, 8.77
143 TH10.1 + + + 0.14 0.07
144 TH11.1 + − + 0.14 0.06
147 TH02.1 + + + 0.14 0.07
152 TH01.5 + + + 0.13 0.07
153 TH21.1 + + + 0.15 0.07
155 TH20.1 + + + 0.16 0.06
156 TH02.2 + + + 0.17 0.07
158 TH08.1 + + + 0.13 0.07
160 TH03.1 + + + 0.13 0.07
161 TH12.1 + + + 0.11 0.06
163 TH19.1 + + + 0.16 0.72 0.75, 0.72
164 TH16.1 + + + 0.15 0.07
most likely represents nonspeciﬁc reactivity since speciﬁcity
of the gp70 CMIA was reported as 99.5% [22]. In summary,
the serologic data obtained in this study suggests a lack of
XMRV infection in our CFS patients and healthy controls.
It is theoretically possible that XMRV replicates at very low
levels in humans and fails to induce a humoral immune
response, or, alternatively, that it is sequestered or latent and
speciﬁc antibody titers have declined to undetectable levels
over time. Although these possibilities cannot be formally
excluded, they seem unlikely given responses observed to
other human retroviruses. The combination of negative mo-
lecular and serologic data do not support an association be-
tween CFS and XMRV or other MLVs. Furthermore, the
recent demonstration that XMRV is a recombinant of two
murine MLVs (23) raises doubts about the validity (24) of
the original XMRV claims in CFS (3).
5. Conclusion
With the serological data added to our original ﬁnding, we
can unequivocally conclude that XMRV is not present in our
CFS patient or healthy control cohort samples. Although we
have detected XMRV gag sequences in three of our samples,
they all tested positive for mouse DNA and tested negative
for XMRV-speciﬁc antibodies. Laboratory mouse strains, as
well as wild mice, all carry numerous endogenous MLVs,
and extreme caution must be taken when testing for murine-
related viruses.
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